

Measure C – Additional Clarification

- Measures C1 & C2 are specific to ***new start*** patients only.
- This measure tracks only those patients initiated on buprenorphine or naltrexone 6 months prior to the reporting date.
- You should not include established patients who have been on MAT prior to the index 6-month timeframe.
- Following the 6-month retention rates of new patients is more sensitive to changes in your MAT program and practices.

Measure C1

	MEASURE DESCRIPTION	DEFINITION
C1	# of patients prescribed buprenorphine or naltrexone long-acting injection 6 months prior who have adhered to this medication continuously for 6 consecutive months	Total number of patients <i>started</i> on either buprenorphine or naltrexone long-acting injection at 6 months prior to the reporting date, and who have remained in care continuously and without interruption. This includes new patients who have started on medication and continued with refills, and who have attended clinic visits. This also includes established patients who may have discontinued treatment for at least 2 months and have been “restarted”.

C1 calculation instructions for reporting period October 1 – December 31, 2019 (i.e.; data that is due January 15, 2020)

1. Calculate patients *started* on MAT in April + patients *started* on MAT in May + patients *started* on MAT in June
2. Then of that total, see how many of those April new start patients are still being prescribed in October, how many of the May new start patients are still being prescribed in November, and how many of the June new start patients are still being prescribed in December. Total that number, and that is C1.

Measure C2

	MEASURE DESCRIPTION	DEFINITION
C2	% of patients prescribed buprenorphine or naltrexone long-acting injection 6 months ago who have continued in treatment for 6 consecutive months of all patients prescribed buprenorphine or naltrexone long-acting injection 6 month prior.	The numerator is calculated in C1. The denominator is calculated by including a count of the total of all patients started on either buprenorphine or naltrexone long-acting injection at 6 months prior to the reporting date. This percentage is to be calculated only on the data panel of eligible patients (i.e., those who started or restarted at 6 months prior to the reporting date) at every quarter of the ATSH project.

C2 calculation instruction for reporting period October 1 – December 31, 2019 (i.e.; data that is due January 15, 2020)

1. The numerator is the same as C1.
2. The denominator is the total sum of new starts that you calculated in step 1 for measure C1 (new starts in April + May + June).

Common Errors Made with this Measure:

- Look at panel in January 2020 and say of all the people in our panel now on MAT, how many have been here for 6 months? Remember, we are looking at the retention rate for new starts or “re-starts” that received medications in April - June. See numerator description above.
- May be tracking patients that have been in their practice for years; not just new starts.

Correct Calculation Example (for data due January 15, 2020 – reporting period October 1 - December 31, 2019):

April: 12 patients total on MAT → 6 of these patients are new starts → 3 of these patients still receiving MAT in October

May: 15 patients total on MAT → 3 of these patients are new starts → 3 of these patients still receiving MAT in November

June: 20 patients total on MAT → 7 of these patients are new starts → 4 of these patients still receiving MAT in December

C1: $3 + 3 + 4 = 10$

C2: Numerator= 10; Denominator= $6 + 3 + 7 = 16$ → 10/16